BRVE
Braveheart Bio, Inc.
Latest Form 4:Purchase$19.8MbyAH Bio Fund IV, L.P. (10% Owner) · filed Aug 11, 2026
Braveheart Bio, Inc. (BRVE) has 11 SEC Form 4 filings (19 transaction rows) in the rolling window, disclosed by 10 distinct insiders. Most recent filing: Aug 11, 2026.
Insiders have net bought $159.0M over the trailing 6 months. The largest single insider purchase in this window was $64.8M by 10% Owner Forbion Growth Opportunities Fund III Cooperatief U.A. on Aug 7, 2026.
- Industry:Biotechnology
- CEO:Travis Murdoch
- HQ:San Francisco, CA, US
- IPO:2026-08-06
Insider Buying
$159.0M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
10
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
AH Bio Fund IV, L.P.First filing | 10% Owner | Purchase | 1,100,000 | $19.8M | Aug 11 | SEC ↗ |
| Director, 10% Owner | Purchase | 1,940,000 | $34.9M | Aug 11 | SEC ↗ | |
Chimovits ErezFirst filing | Director, 10% Owner | Purchase | 1,940,000 | $34.9M | Aug 11 | SEC ↗ |
| 10% Owner | Purchase | 3,600,000 | $64.8M | Aug 7 | SEC ↗ | |
Anderson Michele A.First filing | Chief Development Officer | Purchase | 1,111 | $20K | Aug 7 | SEC ↗ |
Murdoch TravisFirst filing | CEO and President | Purchase | 83,333 | $1.5M | Aug 7 | SEC ↗ |
Lubner David CharlesFirst in 7 months | Director | Purchase | 55,555 | $1000K | Aug 7 | SEC ↗ |
Rickey James PaulFirst filing | Chief Financial Officer | Purchase | 27,777 | $500K | Aug 7 | SEC ↗ |
Malek David IFirst filing | Director | Purchase | 4,166 | $75K | Aug 7 | SEC ↗ |
Viehbacher ChristopherFirst filing | Director | Purchase | 83,333 | $1.5M | Aug 7 | SEC ↗ |
Related companies
Braveheart Bio, Inc. is in the Healthcare sector.